{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T00:22:11Z","timestamp":1794270131091,"version":"4.9.0"},"reference-count":16,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ijantimicag.2026.107897","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T16:39:17Z","timestamp":1782491957000},"page":"107897","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Kidney injury, dialysis, and mortality with vancomycin plus piperacillin\u2013tazobactam or cefepime"],"prefix":"10.1016","volume":"67","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8568-0097","authenticated-orcid":false,"given":"Joseph","family":"Magagnoli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tammy H.","family":"Cummings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8806-4583","authenticated-orcid":false,"given":"Christopher M.","family":"Bland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3889-6178","authenticated-orcid":false,"given":"S. Scott","family":"Sutton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2026.107897_bib0001","doi-asserted-by":"crossref","first-page":"S146","DOI":"10.1097\/CCM.0b013e318168c590","article-title":"Epidemiology of acute kidney injury: how big is the problem?","volume":"36","author":"Hoste","year":"2008","journal-title":"Crit Care Med"},{"key":"10.1016\/j.ijantimicag.2026.107897_bib0002","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.cmi.2020.03.019","article-title":"Acute kidney injury following the concurrent administration of antipseudomonal \u03b2-lactams and vancomycin: a network meta-analysis","volume":"26","author":"Bellos","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2026.107897_bib0003","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02658-18","article-title":"Incidence of acute kidney injury in critically ill patients receiving vancomycin with concomitant piperacillin-tazobactam, cefepime, or meropenem","volume":"63","author":"Blevins","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2026.107897_bib0004","article-title":"Acute kidney injury with combination vancomycin and piperacillin-tazobactam therapy in the ICU: a retrospective cohort study","volume":"56","author":"O\u2019Callaghan","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2026.107897_bib0005","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/phar.1738","article-title":"Comparative incidence of acute kidney injury in critically ill patients receiving vancomycin with concomitant piperacillin-tazobactam or cefepime: a retrospective cohort study","volume":"36","author":"Hammond","year":"2016","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ijantimicag.2026.107897_bib0006","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1002\/phar.1442","article-title":"Comparison of the incidence of vancomycin-induced nephrotoxicity in hospitalized patients with and without concomitant piperacillin-tazobactam","volume":"34","author":"Burgess","year":"2014","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ijantimicag.2026.107897_bib0007","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1002\/phar.1851","article-title":"Is the combination of piperacillin-tazobactam and vancomycin associated with development of acute kidney injury? A meta-analysis","volume":"36","author":"Giuliano","year":"2016","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ijantimicag.2026.107897_bib0008","first-page":"1","article-title":"Nephrotoxicity during vancomycin therapy in combination with piperacillin-tazobactam or cefepime","volume":"61","author":"Rutter","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2026.107897_bib0009","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/AAC.00264-18","article-title":"Incidence of acute kidney injury among patients treated with piperacillin-tazobactam or meropenem in combination with vancomycin","volume":"62","author":"Rutter","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2026.107897_bib0010","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1007\/s00134-022-06811-0","article-title":"Association of vancomycin plus piperacillin-tazobactam with early changes in creatinine versus cystatin C in critically ill adults: a prospective cohort study","volume":"48","author":"Miano","year":"2022","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.ijantimicag.2026.107897_bib0011","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1001\/jama.2023.20583","article-title":"Cefepime vs piperacillin-tazobactam in adults hospitalized with acute infection: the ACORN randomized clinical trial","volume":"330","author":"Qian","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.ijantimicag.2026.107897_bib0016","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41597-022-01899-x","article-title":"MIMIC-IV, a freely accessible electronic health record dataset","volume":"10","author":"Johnson","year":"2023","journal-title":"Sci Data"},{"key":"10.1016\/j.ijantimicag.2026.107897_bib0012","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1093\/jac\/dkaf254","article-title":"Comparing the mortality of patients with sepsis using empirical piperacillin\/tazobactam and cefepime: analysis of the MIMIC-IV database","volume":"80","author":"Lee","year":"2025","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2026.107897_bib0013","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0264281","article-title":"Risk of acute kidney injury associated with anti-pseudomonal and anti-MRSA antibiotic strategies in critically ill patients","volume":"17","author":"C\u00f4t\u00e9","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.ijantimicag.2026.107897_bib0014","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1093\/jac\/dkae001","article-title":"Association between piperacillin\/tazobactam use and acute kidney injury in critically ill patients: a retrospective multicentre cohort study","volume":"79","author":"Tomazini","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2026.107897_bib0015","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1093\/cid\/ciz1189","article-title":"Piperacillin-tazobactam added to vancomycin increases risk for acute kidney injury: fact or fiction?","volume":"71","author":"Avedissian","year":"2020","journal-title":"Clin Infect Dis"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857926001846?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857926001846?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T23:38:55Z","timestamp":1794267535000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857926001846"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":16,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S0924857926001846"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2026.107897","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Kidney injury, dialysis, and mortality with vancomycin plus piperacillin\u2013tazobactam or cefepime","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2026.107897","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107897"}}